| Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry S Haga, N Yamamoto, C Nakai-Murakami, Y Osawa, K Tokunaga, T Sata, ... Proceedings of the National Academy of Sciences 105 (22), 7809-7814, 2008 | 586 | 2008 |
| Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication YH Zheng, D Irwin, T Kurosu, K Tokunaga, T Sata, BM Peterlin Journal of virology 78 (11), 6073-6076, 2004 | 545 | 2004 |
| Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 602 (7896), 300-306, 2022 | 481 | 2022 |
| SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity S Ozono, Y Zhang, H Ode, K Sano, TS Tan, K Imai, K Miyoshi, ... Nature communications 12 (1), 848, 2021 | 422 | 2021 |
| HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes Y Iwabu, H Fujita, M Kinomoto, K Kaneko, Y Ishizaka, Y Tanaka, T Sata, ... Journal of Biological Chemistry 284 (50), 35060-35072, 2009 | 296 | 2009 |
| All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition M Kinomoto, T Kanno, M Shimura, Y Ishizaka, A Kojima, T Kurata, T Sata, ... Nucleic acids research 35 (9), 2955-2964, 2007 | 260 | 2007 |
| The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance I Kimura, Y Kosugi, J Wu, J Zahradnik, D Yamasoba, EP Butlertanaka, ... Cell reports 38 (2), 2022 | 189 | 2022 |
| Successful mouse cloning of an outbred strain by trichostatin A treatment after somatic nuclear transfer S Kishigami, HT Bui, S Wakayama, K Tokunaga, N Van Thuan, T Hikichi, ... Journal of Reproduction and Development 53 (1), 165-170, 2007 | 175 | 2007 |
| Early replication block of human immunodeficiency virus type 1 in monkey cells R Shibata, H Sakai, M Kawamura, K Tokunaga, A Adachi Journal of General Virology 76 (11), 2723-2730, 1995 | 173 | 1995 |
| SARS-CoV-2 B. 1.617 mutations L452R and E484Q are not synergistic for antibody evasion IATM Ferreira, SA Kemp, R Datir, A Saito, B Meng, P Rakshit, ... The Journal of infectious diseases 224 (6), 989-994, 2021 | 147 | 2021 |
| MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins T Tada, Y Zhang, T Koyama, M Tobiume, Y Tsunetsugu-Yokota, ... Nature medicine 21 (12), 1502-1507, 2015 | 143 | 2015 |
| Host restriction factors in retroviral infection: promises in virus-host interaction YH Zheng, KT Jeang, K Tokunaga Retrovirology 9, 1-28, 2012 | 135 | 2012 |
| Topical administration of simvastatin recovers alveolar bone loss in rats H Seto, H Ohba, K Tokunaga, H Hama, M Horibe, T Nagata Journal of periodontal research 43 (3), 261-267, 2008 | 133 | 2008 |
| Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates K Tokunaga, ML Greenberg, MA Morse, RI Cumming, HK Lyerly, ... Journal of virology 75 (15), 6776-6785, 2001 | 106 | 2001 |
| HIV-1 Vpr induces DNA double-strand breaks H Tachiwana, M Shimura, C Nakai-Murakami, K Tokunaga, Y Takizawa, ... Cancer research 66 (2), 627-631, 2006 | 90 | 2006 |
| Function of human immunodeficiency virus type 1 Vpu protein in various cell types H Sakai, K Tokunaga, M Kawamura, A Adachi Journal of General Virology 76 (11), 2717-2722, 1995 | 84 | 1995 |
| Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins N Chutiwitoonchai, M Hiyoshi, Y Hiyoshi-Yoshidomi, M Hashimoto, ... Microbes and infection 15 (4), 280-290, 2013 | 82 | 2013 |
| HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination C Nakai-Murakami, M Shimura, M Kinomoto, Y Takizawa, K Tokunaga, ... Oncogene 26 (4), 477-486, 2007 | 80 | 2007 |
| Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons T Ikeda, KH Abd El Galil, K Tokunaga, K Maeda, T Sata, N Sakaguchi, ... Nucleic acids research 39 (13), 5538-5554, 2011 | 79 | 2011 |
| HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors M Kinomoto, R Appiah-Opong, JAM Brandful, M Yokoyama, N Nii-Trebi, ... Clinical infectious diseases 41 (2), 243-251, 2005 | 78 | 2005 |
